ARS Pharma gains as FDA greenlights nasal spray for allergic reactions

ARS Pharmaceuticals

09/08/2024 16:40

** Shares of drug developer ARS Pharmaceuticals  SPRY.O  up
3.4% at $10.25 in morning trade 
    ** U.S. Food and Drug Administration approved the company's
nasal spray, neffy, as the first needle-free emergency treatment
for allergic reactions, including severe or life threatening
anaphylaxis
    ** Approval of neffy allows use of the treatment in adult
and pediatric patients who weigh at least 30 kilograms 
    ** Anaphylaxis is a severe, life-threatening allergic
reaction that typically involves multiple parts of the body and
is considered a medical emergency
    ** Neffy is a single dose nasal spray given into one nostril
of the patient; a second dose, using a new nasal spray, may be
given in the same nostril if there is no improvement in symptoms
or symptoms worsen - FDA 
    ** Including session gains, SPRY up ~80% YTD

 (Reporting by Bhanvi Satija in Bengaluru)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))